Opus Genetics (NASDAQ:IRD) Insider Ashwath Jayagopal Sells 7,542 Shares

Opus Genetics, Inc. (NASDAQ:IRD) insider Ashwath Jayagopal sold 7,542 shares of the business’s stock in a transaction on Thursday, April 23rd. The shares were sold at an average price of $5.19, for a total transaction of $39,142.98. Following the sale, the insider directly owned 509,233 shares in the company, valued at $2,642,919.27. The trade was a 1.46% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Ashwath Jayagopal also recently made the following trade(s):

• On Monday, March 16th, Ashwath Jayagopal sold 3,719 shares of Opus Genetics stock. The shares were sold at an average price of $5.12, for a total transaction of $19,041.28.

Opus Genetics Price Performance

Shares of IRD stock opened at $5.12 on Tuesday. The company’s fifty day simple moving average is $4.70 and its two-hundred day simple moving average is $3.09. Opus Genetics, Inc. has a 1 year low of $0.81 and a 1 year high of $5.81. The stock has a market capitalization of $365.57 million, a price-to-earnings ratio of -6.24 and a beta of 0.52.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Occudo Quantitative Strategies LP purchased a new position in shares of Opus Genetics during the 4th quarter valued at $25,000. Comerica Bank purchased a new position in shares of Opus Genetics during the 1st quarter valued at $29,000. Virtu Financial LLC purchased a new position in shares of Opus Genetics during the 4th quarter valued at $34,000. Raymond James Financial Inc. grew its position in shares of Opus Genetics by 95.6% during the 3rd quarter. Raymond James Financial Inc. now owns 22,508 shares of the company’s stock valued at $37,000 after purchasing an additional 11,000 shares in the last quarter. Finally, Johnson Investment Counsel Inc. purchased a new position in shares of Opus Genetics during the 4th quarter valued at $40,000. 14.97% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages have issued reports on IRD. Wall Street Zen raised shares of Opus Genetics from a “sell” rating to a “hold” rating in a report on Sunday, March 1st. Lifesci Capital upgraded shares of Opus Genetics to a “strong-buy” rating in a research report on Thursday, February 12th. Cantor Fitzgerald started coverage on shares of Opus Genetics in a research report on Monday, March 30th. They set an “overweight” rating and a $15.00 price target for the company. BTIG Research boosted their price target on shares of Opus Genetics from $7.00 to $12.00 and gave the company a “buy” rating in a research report on Monday, March 2nd. Finally, Craig Hallum set a $9.00 price target on shares of Opus Genetics and gave the company a “buy” rating in a research report on Wednesday, March 11th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Opus Genetics has a consensus rating of “Moderate Buy” and a consensus target price of $10.11.

Key Headlines Impacting Opus Genetics

Here are the key news stories impacting Opus Genetics this week:

• Neutral Sentiment: Management will present at several ophthalmology and industry conferences in May 2026, maintaining visibility with investors and the research community; this is routine corporate outreach rather than an immediate clinical readout. Opus Genetics to Participate in Leading Medical Conferences in May 2026
• Negative Sentiment: Multiple insiders sold stock on April 23rd (CEO George Magrath, CFO Robert Gagnon, COO Joseph Schachle, President Benjamin Yerxa, and others). Combined sales total tens of thousands of shares at roughly $5.18–$5.24 per share. While the company discloses these were sales to cover tax withholding on vested awards (reducing the likelihood of a signal of loss of confidence), clustered insider selling can pressure the share price and likely contributed to today’s weakness. SEC filings: CEO sale CEO Form 4, CFO sale CFO Form 4, other insider filings available in SEC disclosures.

Opus Genetics Company Profile

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.